Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $0
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 10.34am 18/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | $1.81 | Day High | $1.83 | Day Low | $1.81 | |||
| Daily Volume | 8744 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | $1.82 | 5676 | 0 | $1.83 | 6056 | |
Data source: ADVFN
